作为阿司匹林耐药糖尿病患者潜在的血小板抑制剂的复星 - - 一种针对F0的新疗法策略 - - 制ATP合成酶
Isabella Panfoli1, Lavinia Carlini2
1Department of Pharmacy (DIFAR), University of Genoa, 16132 Genova, Italy.
Life (Basel, Switzerland)
|November 27, 2025
概括
复星可能为患有阿司匹林耐药性的2型糖尿病 (T2DM) 患者提供一种新的抗血小板策略. 通过抑制血小板FoF1-ATP合成酶,它可以减少血小板过敏反应和心血管风险.
科学领域:
- 生物化学 生物化学
- 心血管医学 心血管医学
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 2型糖尿病 (T2DM) 涉及血小板功能失调,导致前血栓状况和心血管风险增加.
- 在T2DM中高血糖会损害内皮功能,并促进血小板的高反应性,导致心血管并发症.
- 一部分T2DM患者表现出阿司匹林耐药性,突出显示了替代抗血小板疗法的需要.
研究的目的:
- 审查resveratrol作为T2DM中的新型抗血小板剂的潜力.
- 探索复星的作用机制,特别是其抑制血小板FoF1-ATP合成酶.
- 评估resveratrol作为阿司匹林耐药T2DM患者的替代或协同疗法的疗效.
主要方法:
- 文献综述侧重于复星对血小板功能和FoF1-ATP合成酶的影响.
- 对氧化酸化在血小板激活和T2DM病理生理学中的作用的分析.
- 在T2DM并发症的背景下检查复星的类作用.
主要成果:
- ресвератрол在抑制血小板聚合和调节FoF1-ATP合成酶活性方面表现出潜力.
- 向FoF1-ATP合成酶与白醇可以抵消血糖过高引起的氧化应激在血小板.
- Resveratrol对FoF1-ATP合成酶的作用可能在抗阿司匹林的T2DM中提供治疗优势.
结论:
- 复星对血小板FoF1-ATP合成的抑制为T2DM中新型抗血小板策略提供了有前途的途径.
- 这种机制可能对患有阿司匹林耐药性的T2DM患者特别有益.
- 需要进一步的研究来验证复星作为T2DM管理中的安全有效的抗血小板剂.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
Peripheral Artery Disease III: Interprofessional Care
229
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
229
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Atherosclerosis III: Management
301
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
301
Formation of the Platelet Plug
8.6K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.6K


